Montréal-based Eli Health has raised $17 million in Series A financing to bring its saliva-based hormone-monitoring product to market. The round was led by BDC Capital’s Thrive Venture Fund and includes support from Accelia Capital, TELUS Global Ventures, and other global investors.
Founded in 2019, Eli’s platform tracks cortisol and progesterone levels using a patented FDA-registered Hormometer and app. CEO Marina Pavlovic Rivas says the capital will accelerate manufacturing and expand hormone detection. With $28 million raised to date, Eli claims this is the largest women’s health tech round in Canadian history.
Want to know more? Check out the source code on BetaKit.